Skip to main content

Table 1 Demographics and biomarker profile of enrolled subjects

From: The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease

  Enrolled subjects (N = 295)
Age, years 72.7 ± 8.8
Gender, female % 56%
Educational level, years; median (IQR) 12.0 (6.0–15.0)
MMSE, median (IQR) 27.0 (25.0–28.0)
MCI type, %
 Amnestic MCI 83%
 Non-amnestic MCI 17%
 APOE4 (carrying one or more ε4 allele) 26%
Reported vascular risk factors (no history/under Tx/no Tx)a, %
 Hypertension, % 43/52/4%
 Type 2 diabetes mellitus, % 83/16/1%
 Dyslipidemia, % 67/20/13%
 Smoking, (active smoker/quitted smoker), % 8/8%
 Less than 1 pack per day 11%
 1–2 packs per day 4%
 More than 2 packs per day 1%
Serum lipid profile
 Total cholesterol, mg/dL 190.4 ± 38.0
 LDL cholesterol, mg/dL 112.1 ± 32.9
 HDL cholesterol, mg/dL 52.2 ± 14.7
 Triglyceride, mg/dL 122.0 ± 68.7
 HbA1c 6.09 ± 0.88
 Fasting plasma glucose 102.0 ± 24.0
 Statin use (% in dyslipidemia) 77 (41%)
 Current BMI, kg/m2 23.7 ± 4.3
Imaging biomarkers
 Average Schelten’s score for MTA 1.62 ± 0.72
 Average Fazekas score for WMH 0.90 ± 0.62
 Entorhinal cortical thickness, mm 3.102 ± 0.429
 Hippocampal volume, mm3 3283 ± 588.3
  1. Data were represented as mean ± SD or percentage (%)
  2. Abbreviations: APOE apolipoprotein E, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, MMSE Mini-Mental State Examination, MCI mild cognitive impairment, MTA mesial temporal atrophy, WMH white matter hyperintensity
  3. aHistory of vascular risk factor profile was derived from a questionnaire and coded into three groups: no history (no history), positive history and with medication control (under Tx), and positive history and without medication control (no Tx)